References

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.

2. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61:215-225.

3. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncol. 1999;1:44-51.

4. Smith JS, Wang XY, Qian J, et al. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J Neuropathol Exp Neurol. 2000;59:495-503.

5. Smith JS, Jenkins RB. Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications. Front Biosci. 2000;5:D213-D231.

6. Kitange GJ, Smith JS, Jenkins RB. Genetic alterations and chemother-apeutic response in human diffuse gliomas. Expert Rev Anticancer Ther. 2001;1:595-605.

7. Lin H, Bondy ML, Langford LA, et al. Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. Clin Cancer Res. 1998;4:2447-2454.

8. Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001;93:1246-1256.

9. Tada K, Shiraishi S, Kamiryo T, et al. Analysis of loss of heterozy-gosity on chromosome 10 in patient with malignant astrocytic tumors: correlation with patient age and survival. J Neurosurg. 2001;95:651-659.

10. Rasheed A, Herndon JE, Stenzel TT, et al. Molecular markers of prognosis in astrocytic tumors. Cancer. 2002;94:2688-2697.

11. Terada K, Tamiya T, Daido S, et al. Prognostic value of loss of heterozygosity around three candidate tumor suppressor genes on chromosome 10q in astrocytomas. J Neurooncol. 2002;58:107-114.

12. Simmons ML, Lamborn KR, Takahashi M, et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res. 2001;61:1122-1128.

13. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblas-tomas. Cancer Res. 2000; 60:1383-1387.

14. Feldkamp MM, Roncari L, Lau N, Salhia B, Guha A. Expression of EGFRvIII is a better prognostic marker for GBM than either EGFR expression or the Ki-67 labeling index. Neuro-oncol. 2002;4:343.

15. Peraud A, Watanabe K, Schwechheimer K, Yonekawa Y, Kleihues P, Ohgaki H. Genetic profile of the giant cell glioblastoma. Lab Invest. 1999;79:123-129.

16. Kosel S, Scheithauer BW, Graeber MB. Genotype-phenotype correlation in gemistocytic astrocytomas. Neurosurgery. 2001;48:187-193.

17. Nieder C, Petersen S, Petersen C, Thames HD. The challenge of p53 as prognostic and predictive factor in gliomas. Cancer Treat Rev. 2000;26:67-73.

18. Kraus JA, Glesmann N,Beck M, et al. Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J Neurooncol. 2000;48:89-94.

19. Kraus JA, Wenghoefer M, Glesmann N, et al. TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme. J Neurooncol. 2001;52:263-272.

20. Shiraishi S, Tada K, Nakamura H, et al. Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer. 2002;95:249-257.

21. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994;12:2013-2021.

22. Smith JS, Alderete B, Minn Y, et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene. 1999;18:4144-4152.

23. Mueller W, Hartmann C, Hoffmann A, et al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol. 2002;161:313-319.

24. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473-1479.

25. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 2000;18: 636-645.

26. Burger PC, Pearl DK, Aldape K, et al. Small cell architecture—a histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol. 2001;60:1099-1104.

27. Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN. PTEN is a target of chromosome 10q loss in anaplastic oligoden-drogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol. 2001;159:359-367.

28. Sanson M, Leuraud P, Aguirre-Cruz L, et al. Analysis of loss of chromosome 10q, DMBT1 homozygous deletions, and PTEN mutations in oligodendrogliomas. J Neurosurg. 2002;97:1397-1401.

29. Randazzo L, Scarpace L, Lemke N, et al. Tumoral and chromosomal heterogeneity in oligodendrogliomas detected with medium-throughput 1p/19q LOH analysis. Neuro-oncol. 2002;4:346.

30. Bigner SH, Mark J, Burger PC, et al. Specific chromosomal abnormalities in malignant human gliomas. Cancer Res. 1988;48:405-411.

31. Nigro JM, Takahashi MA, Ginzinger DG, et al. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol. 2001;158:1253-1262.

32. Ohman L, Gedda L, Hesselager G, et al. A new antibody recognizing the vIII mutation of human epidermal growth factor receptor. Tumour Biol. 2002;23:61-69.

33. Watson MA, Perry A, Budhjara V, Hicks C, Shannon WD, Rich KM. Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligodendrogliomas. Cancer Res. 2001;61:1825-1829.

34. Mischel PS, Shai R, Choe GY, et al. Identification of distinctive subtypes of primary glioblastoma multiforme by gene expression profiling. Neuro-oncol. 2002;4:330.

35. Nutt CL, Mani DR, Betensky RA, et al. An accurate microarray class prediction model for high grade gliomas. Neuro-oncol. 2002;4: 345.

36. Misra A, Pellarin M, Moore D, et al. A high-resolution genome wide map of genetic aberrations in human astrocytoma. Neuro-oncol. 2002;4:330.

37. Brennan C, Kim H, Cauwels C, et al. Identification of candidate genetic alterations from array-CGH in human glioblastomas. Neuro-oncol. 2002;4:327.

38. Lal A, Glazer CA, Martinson HM, et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res. 2002;62:3335-3339.

39. Sausville EA, Elsayed Y, Monga M, Kim G. Signal transduction-directed cancer treatments. Annu Rev Pharmacol Toxicol. 2003;43: 199-231.

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment